Niki BioSolutions/$NIKI
1D1W1MYTD1Y5YMAX
Capital at risk
About Niki BioSolutions
Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).
- Ticker
- $NIKI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Princeton, United States
- Website
- www.aptorumgroup.com
NIKI Metrics
BasicAdvanced
$14M
-
-$2.86
-0.83
-
Price and volume
Market cap
$14M
Beta
-0.83
52-week high
$10.39
52-week low
$4.65
Average daily volume
186K
Financial strength
Current ratio
0.451
Quick ratio
0.407
Total debt to equity
0.282
Interest coverage (TTM)
-26.71%
Profitability
Management effectiveness
Return on assets (TTM)
-10.04%
Return on equity (TTM)
-17.05%
Valuation
Price to book
0.18
Price to tangible book (TTM)
0.18
Price to free cash flow (TTM)
-1.442
Free cash flow yield (TTM)
-69.37%
Free cash flow per share (TTM)
-3.274
Growth
Earnings per share change (TTM)
-12.15%
3-year earnings per share growth (CAGR)
-57.08%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.